In search of the Holy Grail
Clinical, pharmacological and haemodynamic effects of serelaxin in acute heart failure

 Acute heart failure (AHF) is a heterogeneous clinical syndrome and severe threatening the patient's life, with worldwide increasing prevalence and presenting very high healthcare costs. However in recent times, been little progress on this topic. Despite extensive research effort, there has been no significant pharmacological advance in the management of AHF patients with respect to mortality and symptoms relief for several decades.
Serelaxin is a recombinant form of human relaxin-2, a peptide hormone of natural origin. Relaxin-2 occurs naturally in women is a mediator of maternal systemic hemodynamics and renal adaptations to an increase in intravascular volume during pregnancy. Relaxin-2 exerts numerous hemodynamic and renal effects in pregnant women, such as increase in arterial compliance with concomitant fall in systemic vascular resistance, and increase in renal blood flow, glomerular filtration rate, and cardiac output.
In studies to date, serelaxin was well tolerated with no apparent safety concerns and exerted favorable haemodynamic effects on pulmonary capillary pressure and pulmonary arterial pressure, but did not significantly change cardiac index, in patients with AHF and normal to high systolic blood pressure.
The hemodynamic effects of serelaxin observed in studies provide important support for plausible improvement in signs and symptoms of congestion observed in patients with AHF. Serelaxin is a promising drug for the treatment of AHF.

Keywords: Acute heart failure - Serelaxin - Clinical trials - Hemodynamic